Waters Corporation 10-Q Summary: Period Ended September 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, and the nine-month period ended on the same date. Waters Corporation is the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, chromatography columns, and related services. Through subsidiaries Micromass and TA Instruments, the Company also leads in mass spectrometry and thermal analysis. The Company reports its operations as a single segment due to the similarity of economic characteristics and production processes across its three operating divisions.
Key Financial Metrics
| Metric | Q3 2001 | Q3 2000 | 9M 2001 | 9M 2000 |
|---|---|---|---|---|
| Net Sales | $202.7M | $192.0M | $610.5M | $569.6M |
| Gross Profit | $129.6M | $121.7M | $388.6M | $361.2M |
| Gross Margin | 63.9% | 63.4% | 63.6% | 63.4% |
| Operating Income | $49.1M | $49.8M | $148.7M | $143.3M |
| Net Income | $38.2M | $37.1M | $116.0M | $94.8M* |
| Diluted EPS | $0.28 | $0.27 | $0.84 | $0.69* |
| Cash from Operations (9M) | $119.9M | $115.5M | ||
| Cash & Equivalents (End of Period) | $164.2M | |||
| Total Debt (Notes Payable) | $1.1M |
*2000 figures include a cumulative effect of a change in accounting principle of $10.8M (net of tax) which reduced 2000 net income.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% in Q3 and 7% for the nine-month period compared to 2000. Excluding the adverse impact of a stronger U.S. dollar, sales growth was 8% for the quarter and 11% for the period.
- Profitability: Gross margins improved slightly due to productivity gains and a shift toward higher-margin chemistry and service products. However, operating income for Q3 decreased 1% year-over-year due to a 12% increase in selling, general, and administrative (SG&A) expenses, driven by headcount growth and unexpected foreign currency transaction losses.
- Cash Position: Cash and cash equivalents more than doubled from $75.5M at year-end 2000 to $164.2M at September 30, 2001, driven by strong operating cash flow and proceeds from stock plans and debt swaps.
- Inventory Build: Inventories increased by $27.8M during the nine-month period, primarily to support new product launches and future sales.
Outlook, Risks, and Management Commentary
- Operational Challenges: Sales growth decelerated in the quarter due to manufacturing setbacks on newly introduced mass spectrometry products, preventing the conversion of strong orders into shipments.
- Order Backlog: Despite shipment delays, order backlog increased by over $7.0 million, reflecting continued strong demand across major geographies.
- Accounting Changes: The Company adopted SFAS 133 (Derivatives) in 2001 with no material impact. Future adoption of SFAS 142 (Goodwill) in 2002 will replace amortization with impairment testing; the impact is currently undetermined.
- Currency Risk: The Company faces exposure to foreign currency fluctuations, utilizing debt swaps and forward contracts to hedge. Unexpected currency losses impacted Q3 results.
- Liquidity: Management believes existing cash balances and available credit facilities are sufficient to fund working capital and capital spending requirements. No dividends are planned.
Investor Verification Checklist
- Verify the resolution of manufacturing setbacks for new mass spectrometry products and their impact on Q4 shipment volumes.
- Monitor the trend of SG&A expenses as a percentage of sales, given the recent increase to 33.0% in Q3.
- Assess the impact of the stronger U.S. dollar on future international revenue growth.
- Review the inventory build-up of $28.0M to ensure it aligns with actual demand and does not lead to future write-downs.
- Confirm the effectiveness of hedging strategies in mitigating foreign currency transaction losses in future quarters.